RxDoctor Payments Data

Richard Milian, MD

Family Medicine · Montgomery, TXNPI 1124464953

Payments from drug & device makers

$13,074in general payments, 2019–2025

Across 819 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$964
  • Pfizer$812
  • GSK$730
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$13,061100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,074 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$232,919
Medicare patients
635
Services billed
2,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$175,497
MounjaroTirzepatide77$119,611
JardianceEmpagliflozin81$93,852
TrulicityDulaglutide45$66,739
JanuviaSitagliptin Phosphate47$63,771
EliquisApixaban52$52,315
MyrbetriqMirabegron27$31,219
Soliqua 100-33Insulin Glargine/Lixisenatide41$29,844
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$27,591
LinzessLinaclotide18$25,686
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,113
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$23,696
Janumet XrSitagliptin Phos/Metformin Hcl19$21,642
FarxigaDapagliflozin Propanediol18$18,386
Synjardy XrEmpagliflozin/Metformin Hcl16$16,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$964$186,350122 claims
Novo NordiskOzempic$2,280$175,497108 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,093$110,10297 claims
MerckJanuvia, Janumet Xr$116$85,41366 claims
PfizerEliquis$812$52,31552 claims
GSKTrelegy Ellipta, Anoro Ellipta$730$35,97953 claims
AbbVieLinzess, Synthroid$712$31,515128 claims
Astellas Pharma US IncMyrbetriq$492$31,21927 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$246$29,84441 claims
AstraZenecaFarxiga$1,451$18,38618 claims
Johnson & JohnsonXarelto$185$15,20211 claims
NovartisEntresto$90$12,26415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Montgomery

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →